F, A., K, A., BA, A., & H, A. (2024). Destabilizing the genome as a therapeutic strategy to enhance response to immune checkpoint blockade: A systematic review of clinical trials evidence from solid and hematological tumors. Frontiers in pharmacology, 14, 1280591. https://doi.org/10.3389/fphar.2023.1280591
Chicago Style (17th ed.) CitationF, Alotaibi, Alshammari K, Alotaibi BA, and Alsaab H. "Destabilizing the Genome as a Therapeutic Strategy to Enhance Response to Immune Checkpoint Blockade: A Systematic Review of Clinical Trials Evidence from Solid and Hematological Tumors." Frontiers in Pharmacology 14 (2024): 1280591. https://doi.org/10.3389/fphar.2023.1280591.
MLA (9th ed.) CitationF, Alotaibi, et al. "Destabilizing the Genome as a Therapeutic Strategy to Enhance Response to Immune Checkpoint Blockade: A Systematic Review of Clinical Trials Evidence from Solid and Hematological Tumors." Frontiers in Pharmacology, vol. 14, 2024, p. 1280591, https://doi.org/10.3389/fphar.2023.1280591.
